Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms

Assessment of Minimal Residual Disease by Next Generation Sequencing in Peripheral Blood as a Complementary Tool for Personalized Transplant Monitoring in Myeloid Neoplasms

Patients with myeloid neoplasms who relapsed after allogenic hematopoietic stem cell transplant (HSCT) have poor prognosis. Monitoring of chimerism and specific molecular markers as a surrogate measure of relapse is not always helpful; therefore, improved systems to detect early relapse are needed....

Full description

Bibliographic Details
Main Authors: Paula Aguirre-Ruiz, Beñat Ariceta, María Cruz Viguria, María Teresa Zudaire, Zuriñe Blasco-Iturri, Patricia Arnedo, Almudena Aguilera-Diaz, Axier Jauregui, Amagoia Mañú, Felipe Prosper, María Carmen Mateos, Marta Fernández-Mercado, María José Larráyoz, Margarita Redondo, María José Calasanz, Iria Vázquez, Eva Bandrés
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Journal of Clinical Medicine
Subjects:
next generation sequencing (NGS)
chimerism
myeloid leukemia
hematopoietic stem cell transplant (HSCT)
minimal residual disease (MRD)
Online Access:https://www.mdpi.com/2077-0383/9/12/3818

Internet

https://www.mdpi.com/2077-0383/9/12/3818

Similar Items